Home > Back to Publisher > Report Information

The World Sleep Disorders Market, 2005-2010: A Market With High Growth Potential

Visiongain
September 14, 2005
87 Pages - SKU: VSG1185928

Abstract Table of Contents Related Reports

The sleep disorder treatment market had sales of $2.03bn in 2004. It is dominated by one product, Ambien indicated for the short-term treatment of insomnia and providing Sanofi-Aventis with an 87% market share. However, in 2006 Ambien loses its patent protection, and the sleep disorder market looks set for dramatic growth and the introduction of at least four new products. In April 2005 year the first real competition for Ambien arrived on the market in the form of Estorra from Sepracor.

The purpose of this market report is to examine the factors that will influence the market and examine why visiongain has a forecast for the market to grow to over $4.4 billion by 2010. The imminent pipeline products are examined in detail and their potential strengths and weaknesses compared. The futures of the older products are assessed. Non-product related factors are considered as the insomnia treatment market has attracted considerable negativity associated with poor side effects and in particular dependency.

The potential for market growth is enormous with only 10% of the estimated potential patient population of 150 million using prescribed pharmaceutical products for insomnia. Although insomnia is by far the most common sleep disorder, this report also considers the markets for:

Narcolepsy
Restless Leg Syndrome (RLS)
Obstructive Sleep Apnea (OSA).
Sanofi-Aventis is the leading company in the sleep disorder market, but over 25 companies are mentioned in this report. The report assesses which companies and products will be key companies by 2010.

Why you should buy this report:

It is a market that will more than double in size by 2010.
It is a market that will change from one dominant product to one with at least 5 key products.
Characteristics of an ideal sleep disorder treatment are compared with the current and pipeline products.
Ambien is key product for Sanofi-Aventis and is at a pivotal point in its life cycle. How this will affect the future sales levels for Sanofi-Aventis is assessed.
Sanofi-Aventis and Sepracor have significantly increased their level of DTC advertising. The importance of this and other non-product related factors are considered.
For anyone with or considering involvement with the sleep disorder market this report is the most recently published report to examine and consider all of the salient factors.

Companies Mentioned in This Report:
Alliance Pharma
Arena Pharmaceutical
Astellas
Celgene
Cephalon
Eli Lilly
Fujisawa Pharmaceutical
GSK
King Pharmaceuticals
Lundbeck
Merck
Merck KgaA
Neurocrine Bioscience
Neurogen
Novartis
Organon
Orphan
Pfizer
Sanofi-Aventis
Sepracor
Shering AG
Shire
Somaxon
Takeda Pharmaceutical
Teva
Wyeth/Elan
Yamanouchi

Please Note: Prior to initiating fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

1. Executive Summary: 1.1 World Sleep Disorder Market Set for an 62% Increase Between 2005 and 2010; 1.2 Aims, Scope and Format of this Report
2. Introduction: 2.1 Sleep Disorder Definitions
3. Disease Overview - What is a Sleep Disorder: 3.1 Sleep Disorders; 3.2 Insomnia; 3.3 Narcolepsy; 3.4 Restless Leg Syndrome; 3.5 Sleep Apnea; 3.6 The Different Stages of Sleep; 3.7 Treatments for Insomnia; 3.8 Ambien's Efficacy Explains its Dominance; 3.9 Myslee - Ambien for the Japanese market; 3.10 Sonata - Niche Market Status; 3.11 Imovane a Low Value Insomnia Product; 3.12 Benzodiazepines are Low Price Sleeping Agents; 3.13 Estorra - Ambien's First Real Competitor; 3.13 Treatments for Narcolepsy; 3.14 Provigil is the Leading Narcoleptic Treatment; 3.15 Ritalin is Also used for Daytime Sleepiness; 3.16 Adderall is Amphetamine Based; 3.17 Xyrem is GHB; 3.18 Anafranil is also Indicated for OCB; 3.19 Adrafinil is an Isomer of Provigil; 3.20 Treatment for Restless Leg Syndrome; 3.21 ReQuip is the Only Treatment for RLS; 3.22 Noctamid is the Only Treatment of OSA
4. World Market Overview for Insomnia - Forecast 2003-2010: 4.1 Ambien Dominates Market, but for How Much Longer?; 4.2 Current Competition For Ambien is Almost Non-Existent; 4.3 To What Extent Will Generic Competition Impact the Market?; 4.4 Branded competition, New Products, New Modes of Action; 4.5 Early and Mid-Stage Pipeline Products; 4.6 Concern Over Side Effects - Fact or Fiction?; 4.7 Characteristics of the Ideal Pharmaceutical Treatment for Insomnia; 4.8 Are these Needs Being Met?; 4.9 Non Product Related Drivers and Restraints; 4.10 Strengths and Weaknesses of Insomnia Treatments; 4.11 Summary Analysis
5. World Sleep Disorder Market by Country Region: 5.1 Is the US Not Sleeping?; 5.2 Will Europe Buy into the Market?; 5.3 The Japanese Market is Catching Up
6. World Market Overview for Other Sleep Disorders: 6.1 Narcolepsy - Old Products for New Markets; 6.2 Restless Leg Syndrome; 6.3 Sleep Apnea - There is An Alternative to Devices and Surgery; 6.4 Non Product Related Drivers and Restraints; 6.5 Summary Analysis
7. Sanofi-Aventis: A Review: 7.1 The Takeover of Aventis by Sanofi was Aggressive; 7.2 Sanofi-Aventis Continues to Expand
8. Conclusion: The Insomnia Market Will Show High Growth: 8.1 Other Sleep Disorders Acquire Limited Interest; 8.2 The Insomnia Market is Poised to Grow Significantly
List Of Tables: Table 2.1 Sleep Disorder Definitions, 2005; Table 3.1 Currently Approved Insomnia Drugs, 2005; Table 3.2 World Sales ($m) for Insomnia Drugs, 2004; Table 3.3 Major Clinical Aspects of Insomnia Drugs, 2005; Table 3.4 Currently Approved Narcolepsy Drugs, 2005; Table 3.5 World Sales ($m) for Narcolepsy Drugs, 2004; Table 3.6 Currently Approved RLS Drugs, 2005; Table 3.7 Currently Approved OSA Drugs, 2005; Table 4.1 World Sales ($m) for Insomnia Drugs, 2003-2010; Table 4.2 World Market Share (%) of Insomnia Drugs, 2004; Table 4.3 World Sales ($m) for Imovane and Sonata, 2003-2010; Table 4.4 World Sales ($m) for Ambien, 2003-2010; Table 4.5 World Sales ($m) for Myslee, 2003-2010; Table 4.6 World Sales ($m) for Estorra, 2003-2010; Table 4.7 World Sales ($m) for Indoplon, 2003-2010; Table 4.8 World Sales ($m) for Rozerem, 2003-2010; Table 4.9 World Sales ($m) for Gaboxadol, 2003-2010; Table 4.10 World Sales ($m) for Posidorm, 2003-2010; Table 4.11 Pipeline Products for Insomnia, 2005; Table 4.12 Summary of Strengths and Weaknesses of Insomnia Drugs; Table 5.1 Potential Insomnia Patient Populations of the Major Pharmaceutical Markets, 2004; Table 6.1 World Sales ($m) for Narcolepsy Drugs, 2004; Table 6.2 World Sales ($m) for Narcolepsy Drugs, 2003-2010; Table 6.3 Approved Drugs for RLS, 2005; Table 6.4 Approved Drugs for OSA, 2005; Table 6.5 World Sales ($m) for Noctamid, 2003-2010; Table 7.1 World Drug Sales in 2003 for Aventis and Sanofi-Synthelabo Prior to the Takeover; Table 7.2 World Drug Sales for the Leading Sanofi-Aventis Prescription Drugs, 2004; Table 7.3 Sanofi-Aventis Sales ($m) by Originator Company, 2004; Table 7.4 World Sales ($bn) of All Leading Drugs of Pfizer, GSK and Samofi-Aventis, 2003-2004
List of Graphs: Graph 1.1 World Sales ($m) for Insomnia Drugs, 2004; Graph 4.1 World Sales ($bn) for All Insomnia Drugs, 2003-2010; Graph 4.2 World Sales ($m) for Main Insomnia Drugs, 2003-2010; Graph 4.3 World Sales ($m) for Sonata, 2003-2010; Graph 4.4 World Sales ($m) for Imovane, 2003-2010; Graph 4.5 World Sales ($m) for Ambien, 2003-2010; Graph 4.6 World Sales ($m) for Myslee, 2003-2010; Graph 4.7 World Sales ($m) for Estorra, 2003-2010; Graph 4.8 World Sales ($m) for Indoplon, 2003-2010; Graph 4.9 World Sales ($m) for Rozerem, 2003-2010; Graph 4.10 World Sales ($m) for Gaboxadol, 2003-2010; Graph 4.11 World Sales ($m) for Posidorm, 2003-2010; Graph 4.12 World Sales ($m) for all Insomnia Drugs, 2003- 2010; Graph 6.1 World Sales ($m) for Non-Insomnia Sleep Disorder Drugs, 2003-2010
List of Figures: Fig 4.1 World Market Share (%) for Insomnia Drugs, 2004; Fig 4.2 Market Share (%) for Insomnia Drugs, 2006; Fig 4.3 World Company Market Share (%), 2004; Fig 4.4 World Company Market Share (%), 2010; Fig 4.5 Market Share (%) for Insomnia Drugs 2010; Fig 5.1 Insomnia Drug Market Share (%) by Country, 2004; Fig 8.1 World Sales ($bn) of the Insomnia Drug Market, 2003-2010

The World Sleep Disorders Market, 2005-2010: A Market With High Growth Potential

Share this report

Other tasks

Research Assistance

Related Markets

CNS/Neurology Reports

Free Alert Me service